drugset / Trial / NCT00425321
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of the study is to evaluate the safety and tolerability of 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with active Rheumatoid Arthritis despite methotrexate therapy.
Timeline
- Start
- 2006-12
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RWJ-445380 | Unknown | 100 mg | Oral |
| Subject | RWJ-445380 | Unknown | 200 mg | Oral |
| Subject | RWJ-445380 | Unknown | 300 mg | Oral |